Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

Curevo筹集1.1亿美元推进Amezosvatein带状疱疹疫苗

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study

——Amezosvatein在二期研究中显示出极佳的免疫原性和改善的耐受性

-- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures

-- Medicxi领投，新投资者OrbiMed、HBM Healthcare Investments和Sanofi Ventures加入

-- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair

——葛兰素史克疫苗业务前主席兼“曲速行动”首席科学顾问蒙塞夫·斯拉维将加入Curevo担任董事会主席

SEATTLE, March 17, 2025-- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles..

西雅图，2025年3月17日——Curevo Vaccine（Curevo），一家致力于开发更高耐受性水痘带状疱疹病毒（VZV）疫苗的私营临床阶段生物技术公司，今天宣布完成了一轮1.1亿美元的B轮融资，以推进其带状疱疹疫苗amezosvatein的开发。

Leading the round is new investor Medicxi, a European biotech-focused investment firm with significant experience investing in vaccine companies such as Vaxcyte and ViceBio. Joining Medicxi is an international group of investment funds including OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma..

领投此轮融资的是新投资者、欧洲生物技术投资公司Medicxi，该公司在投资疫苗企业（如Vaxcyte和ViceBio）方面拥有丰富经验。与Medicxi一同参与投资的是一批国际投资基金，包括OrbiMed、HBM Healthcare Investments、Sanofi Ventures，以及现有投资者RA Capital Management、Janus Henderson Investors、Adjuvant Capital和创始投资者GC Biopharma。

“This Series B round will fund the extension of our successful Phase 2 program into an additional 640 participants, including the key population of adults over age 70, to finalize dose selection ahead of the Phase 3 program,” said Curevo’s CEO, George Simeon, MBA/MPH. “Designed based upon feedback from regulators and other stakeholders, this short extension trial will begin mid-2025 and serve to set the company for clinical, strategic, and regulatory success.”.

“本轮B系列融资将用于把我们成功的第二阶段计划扩展到另外640名参与者，其中包括70岁以上的关键成年人群，以便在第三阶段计划之前最终确定剂量选择，”Curevo首席执行官乔治·西米恩（MBA/MPH）表示。“基于监管机构和其他利益相关者的反馈设计，这个短期扩展试验将于2025年年中开始，并为公司的临床、战略和监管成功奠定基础。”

Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic, helping deliver vaccines against the SARS-CoV-2 virus. He spent nearly 30 years at GlaxoSmithKline, during which he helped shape its vaccine business by contributing to the creation of numerous new vaccines including Shingrix® (shingles), Cervarix® (HPV-induced cervical cancer), Mosquirix® (malaria), Rotarix® (rotavirus gastroenteritis), and Synflorix® (pneumococcal disease)..

此轮融资的同时，Moncef Slaoui博士将加入Curevo担任董事会主席。Slaoui博士最近曾在美国新冠疫情期间担任“曲速行动”（Operation Warp Speed）的首席科学顾问，协助交付针对SARS-CoV-2病毒的疫苗。他在葛兰素史克（GlaxoSmithKline）工作了近30年，期间通过参与研发多种新型疫苗助力塑造了其疫苗业务，这些疫苗包括Shingrix®（带状疱疹）、Cervarix®（HPV引发的宫颈癌）、Mosquirix®（疟疾）、Rotarix®（轮状病毒胃肠炎）和Synflorix®（肺炎球菌病）。

“I have been collaborating with the Curevo team for several weeks now,” stated Dr. Slaoui. “I’m very excited to work with them to help perfect shingles vaccination, adding good tolerability to the exceptional efficacy achieved by the current vaccine. The data so far show Curevo’s adjuvant technology has the attributes to succeed in this endeavor.”.

“我与Curevo团队已经合作了数周，”Slaoui博士表示，“我非常高兴与他们一起努力完善带状疱疹疫苗，在现有疫苗已取得的卓越效力基础上增加良好的耐受性。目前的数据表明，Curevo的佐剂技术具备在这项任务中取得成功的特性。”

Also joining Curevo’s Board of Directors will be Giovanni Mariggi, PhD, co-founder and Partner at Medicxi, an experienced infectious disease investor and board member. “Patients, doctors, and payors are very clear a new shingles vaccine like amezosvatein would be welcome in the global marketplace. Amezosvatein’s activity and improved tolerability profile could allow it to be a significant product in the shingles vaccines market.

此外，Medicxi的联合创始人兼合伙人，经验丰富的传染病投资者和董事会成员乔瓦尼·马里吉（Giovanni Mariggi）博士也将加入Curevo的董事会。“患者、医生和支付方都非常明确，像amezosvatein这样的新型带状疱疹疫苗在全球市场中将受到欢迎。Amezosvatein的活性和改善的耐受性特征可能使其成为带状疱疹疫苗市场中的重要产品。”

We are excited to support Curevo’s plan with a streamlined path to approval,” stated Dr. Mariggi..

我们很高兴支持Curevo的计划，并为其提供一条简化的审批路径，”马里吉博士表示。

Tal Zaks, MD/PhD, will be joining Curevo’s Board of Directors on behalf of OrbiMed. Dr. Zaks is the former Chief Medical Officer of Moderna, where he led development of their mRNA vaccine against the SARS-CoV-2 virus. He previously held senior leadership positions in drug development at GSK and Sanofi.

Tal Zaks，医学博士/哲学博士，将代表OrbiMed加入Curevo董事会。Zaks博士曾是Moderna的首席医学官，领导了针对SARS-CoV-2病毒的mRNA疫苗的开发。他此前曾在GSK和赛诺菲担任药物开发领域的高级领导职务。

“OrbiMed has a long history of investing in biotech companies like Curevo seeking to improve healthcare outcomes while creating long-term shareholder value,” said Dr. Zaks. “The fact amezosvatein contains an optimized version of the TLR4 agonist with a known mechanism of action reduces biological risk while providing the competitive advantage of potentially improved tolerability, which should position it as the first choice for people who want to be protected from shingles.”.

“OrbiMed 在投资像 Curevo 这样致力于改善医疗保健效果并创造长期股东价值的生物技术公司方面有着悠久的历史，”扎克斯博士说。“amezosvatein 含有经过优化的 TLR4 激动剂版本，其作用机制已知，这降低了生物学风险，同时提供了潜在改善耐受性的竞争优势，应该使其成为希望预防带状疱疹的人们的首选。”

About amezosvatein

关于amezosvatein

‘Amezosvatein’ is the assigned non-proprietary name for CRV-101, a non-mRNA adjuvanted subunit vaccine under investigation by Curevo. Like Shingrix, amezosvatein uses a subunit protein antigen called glycoprotein ‘E’ (gE). Targeting the gE antigen is proven to elicit a long-term, protective immune response to prevent shingles.

‘Amezosvatein’ 是 Curevo 公司正在研发的非 mRNA 佐剂亚单位疫苗 CRV-101 的指定非专有名称。与 Shingrix 类似，amezosvatein 使用一种名为糖蛋白 ‘E’ (gE) 的亚单位蛋白抗原。研究表明，针对 gE 抗原能够引发长期的保护性免疫反应，从而预防带状疱疹。

Amezosvatein’s adjuvant contains an optimized version of the TLR4 agonist proven by Shingrix to be biologically active in shingles vaccination. Amezosvatein was engineered to maintain exceptional efficacy and have a best-in-class tolerability profile. The SLA-SE adjuvant formulation was developed at Seattle-based Access to Advanced Health Institute (AAHI) and amezosvatein was licensed from the Mogam Institute for Biomedical Research, a research institute funded by South Korea’s GC Biopharma..

阿美佐伐汀的佐剂含有经欣rix证明在带状疱疹疫苗接种中具有生物活性的TLR4激动剂的优化版本。阿美佐伐汀经过设计，以保持卓越的疗效，并具有同类最佳的耐受性特征。SLA-SE佐剂配方是在西雅图的高级健康获取研究所（AAHI）开发的，阿美佐伐汀则从韩国GC生物制药公司资助的研究机构莫甘生物医学研究所获得授权。

About Curevo

关于Curevo

Curevo is a privately held, clinical-stage biotechnology company based near Seattle dedicated to reducing the burden of infectious disease by developing vaccines with improved tolerability and accessibility. Curevo’s lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain.

Curevo是一家位于西雅图附近的私营临床阶段生物技术公司，致力于通过开发具有更高耐受性和可及性的疫苗来减轻传染病的负担。Curevo的主要产品是amezosvatein，这是一种非mRNA佐剂亚单位疫苗，用于预防带状疱疹——一种严重的医学病症，表现为疼痛的水疱性皮疹，10-18%的患者还会发展为严重且持久的神经痛。

The current $4+ billion shingles vaccine market is characterized by accessibility issues and vaccine hesitancy/dose avoidance related to vaccine tolerability. For more information visit https://curevovaccine.com/..

当前价值 40 亿美元以上的带状疱疹疫苗市场，其特点是存在可及性问题，以及与疫苗耐受性相关的疫苗犹豫和剂量规避。欲了解更多信息，请访问 https://curevovaccine.com/。

About Medicxi

关于Medicxi

Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need.

Medicxi是一家专注于医疗保健的投资公司，其使命是创建并投资于覆盖整个药物开发领域的公司。凭借在药物开发和公司创建方面超过二十年的深厚专业知识，Medicxi投资于早期和晚期治疗领域，拥有能够满足明确未满足医疗需求的产品愿景。

For more information, please visit: https://www.medicxi.com..

有关更多信息，请访问：https://www.medicxi.com。

About OrbiMed

关于奥博资本

OrbiMed is a leading global healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, via private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies.

OrbiMed是一家全球领先的医疗保健投资公司，管理着大约170亿美元的资产。OrbiMed通过私募股权基金、公开股权基金以及特许权/信贷基金，在全球范围内对医疗保健行业进行投资，从初创企业到大型跨国公司皆有涉及。OrbiMed致力于成为首选的资本提供者，提供定制的融资解决方案和广泛的全球团队资源，以帮助建立世界级的医疗保健公司。

OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.orbimed.com..

奥博资本团队由100多名专业人士组成，分布于纽约、伦敦、旧金山、上海、香港、孟买、赫兹利亚及其他主要全球市场。欲了解更多信息，请访问www.orbimed.com。

About HBM Healthcare Investments

关于HBM医疗保健投资

Switzerland-based HBM Healthcare Investments focuses on the healthcare sector, holding and managing an international portfolio of promising companies in the human medicine, biotechnology, medical technology, diagnostics, and related areas. Many of these companies have their lead products already available on the market or are at an advanced stage of development.

总部位于瑞士的HBM医疗保健投资公司专注于医疗保健领域，持有并管理着一个国际化的、涵盖人类医学、生物技术、医疗技术、诊断及相关领域的有前景的公司组合。这些公司中的许多已经将其主导产品推向市场或处于开发的高级阶段。

The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (SIX:HBMN)..

被投资公司受到密切的跟踪，并在其战略方向上得到积极的指导。这使得HBM医疗投资成为投资大型制药和生物技术公司的一个有趣的替代选择。HBM医疗投资拥有国际化的股东基础，并在瑞士证券交易所（SIX:HBMN）上市。

About Sanofi Ventures

关于赛诺菲风险投资

Sanofi Ventures is the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies. The firm supports pioneering innovations in biotechnology, digital health, and life sciences aligning with Sanofi’s mission to bring life-changing treatments to patients worldwide.

赛诺菲风投是赛诺菲的企业风险投资部门，专注于投资有前景的早期医疗保健公司。该公司支持与赛诺菲使命一致的生物技术、数字健康和生命科学领域的开创性创新，致力于为全球患者带来改变生命的治疗方法。

For more information, please visit www.sanofiventures.com..

欲了解更多信息，请访问 www.sanofiventures.com。

About RA Capital

关于RA资本

Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond.

RA Capital Management 成立于2004年，是一家多阶段投资管理公司，专注于在公共和私人医疗保健、生命科学以及行星健康领域的基于证据的投资。RA Capital 创建并资助创新公司，从私人种子轮到公开后续融资，助力管理团队从初创阶段到商业化及更远阶段的价值创造。

RA Capital's knowledge engine is guided by its TechAtlas internal research division, and Raven, RA Capital's healthcare incubator, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over $10 billion in assets under management..

RA资本的知识引擎由其内部研究部门TechAtlas指导，RA资本的医疗孵化器Raven为创业者和创新者提供了一个协作且全面的平台，以探索新颖和重新构想的事物。RA资本拥有150多名员工，管理资产超过100亿美元。

About Janus Henderson Investors

关于詹纳斯亨德森投资者

Janus Henderson Investors exists to help clients achieve their long-term financial goals. Its active management offers clients the opportunity to outperform passive portfolios over the course of market cycles. With more than 360 investment professionals, Janus Henderson Investors provides access to some of the industry’s most talented and innovative thinkers, spanning equities, fixed income, multi-asset, and alternatives, globally.

骏利亨德森投资公司旨在帮助客户实现其长期财务目标。其主动管理为客户提供在市场周期中跑赢被动投资组合的机会。骏利亨德森投资公司拥有360多位投资专业人士，为客户提供全球范围内一些行业内最有才华和创新思维的专家支持，涵盖股票、固定收益、多资产和另类投资。

Its investment teams blend insight, originality, and precision with rigorous analysis, structured processes, and robust risk management. Janus Henderson Investors builds client partnerships on openness and trust, channeling expertise from across the business and communicating the views of its experts in a timely and relevant way.

其投资团队融合了洞察力、原创性和精确性，并通过严谨的分析、结构化的流程和强有力的风险管理来实现。骏利亨德森投资者以开放和信任为基础建立客户合作关系，汇集整个业务领域的专业知识，并以及时且相关的方式传达其专家的观点。

https://www.janushenderson.com/.

https://www.janushenderson.com/.

About Adjuvant Capital

关于辅助资本

Headquartered in New York, with offices in Zürich, Adjuvant is a global life science investment fund built to accelerate the development of new technologies for the world's most pressing public health challenges. Backed by prominent healthcare and emerging market investors, Adjuvant draws upon its network of scientists, public health experts, biopharmaceutical industry veterans, and development finance professionals to identify new investment opportunities.

总部位于纽约，并在苏黎世设有办事处，Adjuvant是一家全球生命科学投资基金，致力于加速为世界最紧迫的公共卫生挑战开发新技术。Adjuvant得到了知名医疗保健和新兴市场投资者的支持，依托其科学家、公共卫生专家、生物制药行业资深人士和发展金融专业人士的网络来发掘新的投资机会。

Adjuvant invests in companies developing promising new vaccines, therapeutics, diagnostics, and medical devices targeting high-burden infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, with a commitment to make these interventions accessible globally. For more information, visit http://www.adjuvantcapital.com.

Adjuvant投资于那些开发有前途的新疫苗、治疗药物、诊断工具和医疗设备的公司，这些产品针对高负担的传染病、妇幼健康、抗菌素耐药性和营养不良，并承诺使这些干预措施在全球范围内可及。欲了解更多信息，请访问http://www.adjuvantcapital.com。

About GC Biopharma

关于GC生物制药

Founding investor GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yongin, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines and expanded its global presence with the successful USA market entry of ALYGLO™ (intravenous immunoglobulin G) in 2024.

创始投资者GC Biopharma（前身为Green Cross Corporation）是一家总部位于韩国龙仁的生物制药公司。该公司在血浆衍生物和疫苗的开发与生产方面拥有超过半个世纪的经验，并于2024年通过ALYGLO™（静脉注射免疫球蛋白G）成功进入美国市场，进一步扩大了其全球影响力。

In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platforms to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation).

为了实现满足未来医疗需求的使命，GC Biopharma继续通过利用其在蛋白质、mRNA和脂质纳米颗粒（LNP）药物递送平台工程方面的核心研发能力，推动创新，开发罕见病领域以及免疫学与炎症（I&I）领域的治疗药物。

To learn more about the company, visit https://www.gcbiopharma.com/eng/.

要了解有关公司的更多信息，请访问 https://www.gcbiopharma.com/eng/。

Shingrix®, Cervarix®, Mosquirix®, Rotarix®, and Synflorix® are registered trademarks of GlaxoSmithKline, PLC.

Shingrix®、Cervarix®、Mosquirix®、Rotarix® 和 Synflorix® 是葛兰素史克公司的注册商标。